Cargando…
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
BACKGROUND: In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on the clini...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325739/ https://www.ncbi.nlm.nih.gov/pubmed/30621618 http://dx.doi.org/10.1186/s12885-018-5244-2 |
_version_ | 1783386177048412160 |
---|---|
author | Blomstrand, Hakon Scheibling, Ursula Bratthäll, Charlotte Green, Henrik Elander, Nils O. |
author_facet | Blomstrand, Hakon Scheibling, Ursula Bratthäll, Charlotte Green, Henrik Elander, Nils O. |
author_sort | Blomstrand, Hakon |
collection | PubMed |
description | BACKGROUND: In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on the clinical benefit and toxicity of the combination regimen in a real world setting. In addition the value for patients with locally advanced rather than metastatic aPDA has been unclear, since the former category of patients was not included in the MPACT trial. METHODS: A multicentre retrospective observational study in the South Eastern Region of Sweden was performed, with the first 75 consecutive patients diagnosed with aPDA (both locally advanced and metastatic disease) who received first-line treatment with Gem/NabP. RESULTS: In the overall population median progression free survival (PFS) and overall survival (OS) were 5.2 (3.4–7.0 95% CI) and 10.9 (7.8–14.0 95% CI) months, respectively. Patients with metastatic disease displayed a median OS of 9.4 (4.9–13.9) and a median PFS of 4.5 (3.3–5.7) months whereas the same parameters in the locally advanced subgroup were 17.1 (7.6–26.6) and 6.8 (5.2–8.4) months, respectively. Grade 3–4 hematologic toxicity was recorded: Neutropenia, leukopenia, thrombocytopenia, and anaemia were observed in 23, 20, 5, and 4% of patients, respectively. Dose reductions were performed in 80% of the patients. CONCLUSION: This study confirms the effectiveness and safety of first-line Gem/NabP in both locally advanced and metastatic PDA in a real world setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5244-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6325739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63257392019-01-11 Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer Blomstrand, Hakon Scheibling, Ursula Bratthäll, Charlotte Green, Henrik Elander, Nils O. BMC Cancer Research Article BACKGROUND: In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on the clinical benefit and toxicity of the combination regimen in a real world setting. In addition the value for patients with locally advanced rather than metastatic aPDA has been unclear, since the former category of patients was not included in the MPACT trial. METHODS: A multicentre retrospective observational study in the South Eastern Region of Sweden was performed, with the first 75 consecutive patients diagnosed with aPDA (both locally advanced and metastatic disease) who received first-line treatment with Gem/NabP. RESULTS: In the overall population median progression free survival (PFS) and overall survival (OS) were 5.2 (3.4–7.0 95% CI) and 10.9 (7.8–14.0 95% CI) months, respectively. Patients with metastatic disease displayed a median OS of 9.4 (4.9–13.9) and a median PFS of 4.5 (3.3–5.7) months whereas the same parameters in the locally advanced subgroup were 17.1 (7.6–26.6) and 6.8 (5.2–8.4) months, respectively. Grade 3–4 hematologic toxicity was recorded: Neutropenia, leukopenia, thrombocytopenia, and anaemia were observed in 23, 20, 5, and 4% of patients, respectively. Dose reductions were performed in 80% of the patients. CONCLUSION: This study confirms the effectiveness and safety of first-line Gem/NabP in both locally advanced and metastatic PDA in a real world setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5244-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-08 /pmc/articles/PMC6325739/ /pubmed/30621618 http://dx.doi.org/10.1186/s12885-018-5244-2 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Blomstrand, Hakon Scheibling, Ursula Bratthäll, Charlotte Green, Henrik Elander, Nils O. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer |
title | Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer |
title_full | Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer |
title_fullStr | Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer |
title_full_unstemmed | Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer |
title_short | Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer |
title_sort | real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325739/ https://www.ncbi.nlm.nih.gov/pubmed/30621618 http://dx.doi.org/10.1186/s12885-018-5244-2 |
work_keys_str_mv | AT blomstrandhakon realworldevidenceongemcitabineandnabpaclitaxelcombinationchemotherapyinadvancedpancreaticcancer AT scheiblingursula realworldevidenceongemcitabineandnabpaclitaxelcombinationchemotherapyinadvancedpancreaticcancer AT bratthallcharlotte realworldevidenceongemcitabineandnabpaclitaxelcombinationchemotherapyinadvancedpancreaticcancer AT greenhenrik realworldevidenceongemcitabineandnabpaclitaxelcombinationchemotherapyinadvancedpancreaticcancer AT elandernilso realworldevidenceongemcitabineandnabpaclitaxelcombinationchemotherapyinadvancedpancreaticcancer |